Laryngopharyngeal reflux symptoms improve before changes in physical findings

Laryngoscope. 2001 Jun;111(6):979-81. doi: 10.1097/00005537-200106000-00009.

Abstract

Background: Patients with laryngopharyngeal reflux (LPR) undergoing treatment appear to have improvement in symptoms before the complete resolution of the laryngeal findings.

Objective: To determine whether patients with LPR experience an improvement in symptoms before the complete resolution of the laryngeal findings.

Methodology: Forty consecutive patients with LPR documented by double-probe pH monitoring were evaluated prospectively. Symptom response to therapy with proton pump inhibitors was assessed at 2, 4, and 6 months of treatment with a self-administered reflux symptom index (RSI). In addition, transnasal fiberoptic laryngoscopy (TFL) was performed and a reflux finding score (RFS) was determined for each patient at each visit.

Results: The mean RSI at entry was 19.3 (+/- 8.9 standard deviation) and it improved to 13.9 (+/- 8.8) at 2 months of treatment (P <.05). No further significant improvement was noted at 4 months (13.1 +/- 9.8) or 6 months (12.2 +/- 8.1) of treatment. The RFS at entry was 11.5 (+/- 5.2), and it improved to 9.4 (+/- 4.7) at 2 months, 7.3 (+/- 5.5) at 4 months, and 6.1 (+/- 5.2) after 6 months of treatment (P <.05 with trend).

Conclusions: Symptoms of LPR improve over 2 months of therapy. No significant improvement in symptoms occurs after 2 months. This preliminary report demonstrates that the physical findings of LPR resolve more slowly than the symptoms and this continues throughout at least 6 months of treatment. These data imply that the physical findings of LPR are not always associated with patient symptoms, and that treatment should continue for a minimum of 6 months or until complete resolution of the physical findings.

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents / therapeutic use*
  • Benzimidazoles / therapeutic use
  • Female
  • Follow-Up Studies
  • Gastric Acidity Determination
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / diagnosis
  • Gastroesophageal Reflux / drug therapy*
  • Humans
  • Lansoprazole
  • Laryngeal Diseases / diagnosis
  • Laryngeal Diseases / drug therapy*
  • Laryngeal Diseases / etiology
  • Laryngoscopy
  • Male
  • Middle Aged
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Pharyngeal Diseases / diagnosis
  • Pharyngeal Diseases / drug therapy*
  • Pharyngeal Diseases / etiology
  • Proton Pump Inhibitors*
  • Proton-Translocating ATPases / antagonists & inhibitors
  • Rabeprazole
  • Treatment Outcome

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Benzimidazoles
  • Proton Pump Inhibitors
  • Lansoprazole
  • Rabeprazole
  • Proton-Translocating ATPases
  • Omeprazole